“…Linking orthosteric ( 1 , 3 , and 4 ) and allosteric ( 11 and 12 ) MR ligands with a M 2 R preferring dibenzodiazepinone-type MR antagonist ( 8 ) yielded a series of heterodimeric ligands ( 34 , 38 , 39 , 43 , 44 , 46 , 48 , 50–52 , 60 , 61 , 63 , 64 , 66 , 67 , 69 , 70 , and 72 ). The “ 8–1 ” type dimeric ligand 46 (UR-SK75), containing a piperazine moiety in the linker, exhibited a higher M 2 R affinity (p K i 10.14) and selectivity [expressed as the ratio of K i values (M 1 /M 2 /M 3 /M 4 /M 5 ): 23:1:180:29:430] compared to monomeric (such as 8 ( 46 ) and 10 ( 22 , 23 )) and homodimeric (e.g., 18 ( 22 ) and 19 ( 23 )) dibenzodiazepinone-type ligands. High M 2 R affinity of all dibenzodiazepinone-type heterodimeric ligands (p K i > 8.3, Table 1 ), as also reported for monomeric dibenzodiazepinone-type ligands, 22 suggested a minor influence of the second pharmacophore on M 2 R binding, indicating that the high M 2 R affinity of these compounds is mediated by the “dibenzodiazepinone” pharmacophore, which binds most likely to the orthosteric binding site of the M 2 R. This is supported by the proposed binding mode of 10 and 19 at the M 2 R, 23 by saturation-binding studies using the radioligands [ 3 H] 44 ([ 3 H]UR-SK71) and [ 3 H] 64 ([ 3 H]UR-SK59), and by the fact that compounds containing M 1 R/M 4 R selective agonist 1 ( 49 ) as a second pharmacophore ( 43 , 44 , 46 , 60 , and 61 ) proved to be M 2 R-preferring ligands.…”